Combination antiretroviral therapy is associated with reduction in liver fibrosis scores in patients with HIV and HBV co-infection

Table 1 Baseline characteristics of the study population

Characteristic	HIV/HBV co-infected (n = 458)
Male (n, %)	362(79.0)
Age Years, Mean ± SD	46 ± 12
BMI, Mean ± SD	21.37 ± 2.43
Alcohol use, yes (n, %)	13(2.8)
ALT IU/L, Mean ± SD	42.8 ± 4.3
AST IU/L, Mean ± SD	44.7 ± 4.9
Platelets 10⁹/L, Mean ± SD	159 ± 4
FIB-4, Mean ± SD	4.869 ± 0.913
< 1.45(n, %)	156(34.1)
1.45–3.25(n, %)	164(35.8)
> 3.25(n, %)	138(30.1)
CD4 cell count, Mean ± SD	161 ± 11
CD4 < 200 cells/ul(n, %)	262(57.2)
CD4 ≥ 200 cells/ul(n, %)	196(42.8)
HIV RNA > 20 copies/ml(n, %) *	145(31.7)
HBV DNA > 20 copies/ml(n, %) §	189(41.3)
HBeAg positive(n, %)	125(27.3)
Anti-HBe positive(n, %)	189(41.3)
Treatment history
Months of HIV diagnosis, Mean ± SD	38.03 ± 2.50
Months of ART treatment, Mean ± SD	35.89 ± 4.72
TDF/3TC based regimen (n, %)	246/317 (77.6)
AZT/3TC based regimen (n, %)	71/317 (22.4)

^*The 145 individuals who have detectable VL, 141 (30.8%) individuals didn’t received ART treatment. The remaining 4 individuals received ART, but the HIV-RNA levels were low (46 copies/ml; 52 copies/ml; 106 copies/ml and 896 copies/ml, respectively). §Among the 189 individuals, 66.1%(125/189) of them were overlap with HIV-RNA positive. In HBV DNA + /HIV-RNA + and HBV DNA + /HIV-RNA- group, FIB-4 were 5.152 ± 0.551 and 4.403 ± 0.576, respectively. The difference between the two groups was not statistically significant (t = 0.817, P = 0.414)

ISSN: 1742-6405